BARBERIO, BRIGIDA
 Distribuzione geografica
Continente #
NA - Nord America 2.283
AS - Asia 459
EU - Europa 396
AF - Africa 7
SA - Sud America 4
OC - Oceania 2
Totale 3.151
Nazione #
US - Stati Uniti d'America 2.273
SG - Singapore 228
IT - Italia 173
CN - Cina 143
FR - Francia 59
FI - Finlandia 53
GB - Regno Unito 37
VN - Vietnam 34
IN - India 23
DE - Germania 21
IE - Irlanda 13
RU - Federazione Russa 11
SE - Svezia 9
NL - Olanda 7
HK - Hong Kong 6
CA - Canada 5
IR - Iran 5
PH - Filippine 5
BR - Brasile 4
EG - Egitto 4
MX - Messico 4
ID - Indonesia 3
JP - Giappone 3
AT - Austria 2
CH - Svizzera 2
IL - Israele 2
IQ - Iraq 2
KR - Corea 2
LS - Lesotho 2
PL - Polonia 2
TW - Taiwan 2
UA - Ucraina 2
AU - Australia 1
BG - Bulgaria 1
DK - Danimarca 1
ES - Italia 1
JM - Giamaica 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
Totale 3.151
Città #
Fairfield 397
Chandler 210
Singapore 198
Santa Clara 144
Ashburn 134
Seattle 134
Woodbridge 134
Cambridge 127
Houston 121
San Diego 91
Wilmington 77
Boardman 72
Medford 59
Princeton 59
Padova 54
Helsinki 50
Roxbury 50
Beijing 47
Ann Arbor 46
Des Moines 40
Dong Ket 30
Pune 17
Milan 16
London 10
Ogden 8
Dublin 7
Washington 6
Curtarolo 5
Hong Kong 5
Menlo Park 5
Norwalk 5
Genoa 4
Guangzhou 4
Manila 4
Mexico City 4
New York 4
Prescot 4
Shanghai 4
Cagliari 3
Deiva Marina 3
Hamilton 3
Hanoi 3
Hounslow 3
Kish 3
Lappeenranta 3
Liverpool 3
Manchester 3
Rome 3
San Martino Buon Albergo 3
São Paulo 3
Verona 3
Zhengzhou 3
Ahmedabad 2
Alexandria 2
Amiens 2
Aversa 2
Baghdad 2
Brendola 2
Calenzano 2
Campi Bisenzio 2
Cernusco sul Naviglio 2
Changsha 2
Chicago 2
Chiswick 2
Daita 2
Imola 2
Jacurso 2
Kaohsiung City 2
Kharkiv 2
Lanzhou 2
Las Vegas 2
Los Angeles 2
Maseru 2
Padang 2
Palermo 2
Ponte Lambro 2
San Jose 2
Shenyang 2
Stafford 2
Tel Aviv 2
Venice 2
Vienna 2
Vigodarzere 2
Zurich 2
Albuquerque 1
Almaty 1
Amsterdam 1
Andover 1
Auckland 1
Bologna 1
Borås 1
Broomfield 1
Cairo 1
Casier 1
Central 1
Chongqing 1
Cigognola 1
Clifton 1
Corridonia 1
Council Bluffs 1
Totale 2.508
Nome #
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis 114
REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY 100
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab 92
Gastrointestinal: An unusual rectal finding in a patient with ulcerative colitis 89
Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital 86
Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. 82
Updates in the field of non-esophageal gastroesophageal reflux disorder 81
A survey on nutritional knowledge in coeliac disease compared to inflammatory bowel diseases patients and healthy subjects 81
A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach 76
Advancements in the use of manometry and impedance testing for esophageal functional disorders 75
Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak 74
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 73
Vonoprazan may provide better results than ppis in helicobacter pylori eradication and beyond – is it time for a change? 69
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf: Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio 69
Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak 68
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 67
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 66
Perception of the COVID-19 pandemic among patients with inflammatory bowel disease in the time of telemedicine: cross-sectional questionnaire study 64
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis 63
Inflammatory Bowel Disease and Sleep Disturbance: As Usual, Quality Matters 60
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 59
Medical and gastroenterological education during the COVID-19 outbreak 57
The Lyon Consensus: Does it differ from the previous ones? 57
Vonoprazan fumarate for the treatment of gastric ulcers: A short review on emerging data 54
Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario 53
Prevention Strategies for Esophageal Cancer-An Expert Review 52
Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria 50
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis 50
The risk of malignancies in celiac disease—A literature review 49
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 48
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 47
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis 45
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients 44
Eosinophilic esophagitis and biologics 43
Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study 43
A Peculiar Cutaneous Manifestation in a Patient With Crohn's Disease 42
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation 41
Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations 39
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? 37
Hospitalisation for drug infusion did not increase levels of anxiety and the risk of disease relapse in patients with inflammatory bowel disease during covid-19 outbreak 36
Reply to letter to the editor: Nlr and plr as novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf 36
Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases 36
Response to Khalaf et al 35
Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together? 34
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis 33
Bariatric Surgery and Esophageal Function: An Eternal Impasse? 33
An "Old" Esophagus 31
Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis 30
Eosinophilic esophagitis: from pathophysiology to management 29
Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases 29
MICRO-RNAs TISSUTALI COME BIOMARCATORI DI DIAGNOSI PRECOCE E MONITORAGGIO IN PAZIENTI CON CANCRO DEL COLONRETTO ASSOCIATO A MALATTIA INFIAMMATORIA CRONICA INTESTINALE 28
Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials: Future Treatments for EGIDS: Systematic Review 27
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 26
Myocarditis and inflammatory bowel diseases: A single-center experience and a systematic literature review 26
Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms 25
Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis 25
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis 23
Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study 22
Modern diagnosis of early esophageal cancer: From blood biomarkers to advanced endoscopy and artificial intelligence 21
Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis 21
Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment? 20
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility 19
Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome 18
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 17
Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis 17
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis 16
Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey 16
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series 14
Systematic review with meta-analysis: artificial intelligence in the diagnosis of oesophageal diseases 12
Non-hepatic solid organ transplant in patients with inflammatory bowel disease: an ECCO CONFER Multicentre Case Series 11
Totale 3.225
Categoria #
all - tutte 21.058
article - articoli 20.972
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202087 0 0 0 0 0 1 4 7 10 30 31 4
2020/2021596 29 2 82 2 5 110 110 37 65 39 14 101
2021/2022927 38 56 66 43 115 105 86 44 106 46 42 180
2022/2023514 106 11 24 69 69 59 6 34 57 13 47 19
2023/2024495 41 53 53 41 38 45 45 36 29 14 59 41
2024/2025606 6 172 99 52 225 52 0 0 0 0 0 0
Totale 3.225